Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Endometrial Carcinoma Study

What is endometrial cancer?

Endometrial cancer develops in the cells that form the inner lining of the uterus, or the endometrium, and is one of the most common cancers of the female reproductive system among American women. In 2010, approximately 43,000 women in the United States were estimated to have been diagnosed with and almost 8,000 to have died of endometrial cancer.1 This cancer occurs most commonly in women aged 60 years or older. About 69% of endometrial cancers are diagnosed at an early stage, and as a result, about 83% of women survive five years following the time of diagnosis. Additional information on endometrial (uterine) cancer.

What have TCGA researchers learned about endometrial carcinoma?

  • Four molecular subtypes of endometrial cancer are: POLE ultramutated, microsatellite instability hypermutated, copy number low, and copy number high.
  • Endometrial cancer shares genomic features with serous ovarian cancer, the basal-like subtype of breast cancer, and colorectal cancer.
  • Some endometrioid and serous endometrial tumors are molecularly distinct, while others are similar, suggesting some may benefit from a common treatment.
    • Serous and some of the endometrioid tumors are characterized by frequent mutations in TP53, extensive copy number alterations, and few methylation changes.
    • Other endometrioid tumors are characterized by few copy number alterations, scarce mutations in TP53, and frequent mutations in PTEN and KRAS
Email